Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06190093 · ClinicalTrials.gov registry record · Phase 3
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
A Phase 3 study, sponsored by Outlook Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT06190093: Completed Phase 3 study, sponsored by Outlook Therapeutics.
NCT06190093 is a Phase 3 study that has completed, run by Outlook Therapeutics. The registered enrollment target is 400 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06190093, a Phase 3 study, has completed, sponsored by Outlook Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
Primary Outcome
BCVA to be assessed as letters read using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts. A positive change represents an improvement in visual acuity.
Interventions
- BIOLOGICAL bevacizumab
- BIOLOGICAL ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-01-24 |
| Est. Completion | 2024-12-05 |
| Phase | Phase 3 |
What the finished NCT06190093 record still lists
NCT06190093 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 2 interventions - of which bevacizumab is the first listed.
NCT06190093 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06190093 about?
NCT06190093 is a clinical study titled "A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)". Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
What is the current status of trial NCT06190093?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2024-01-24. Estimated completion is 2024-12-05.
What interventions are being tested in trial NCT06190093?
The interventions under investigation include: bevacizumab (BIOLOGICAL), ranibizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06190093?
This trial is sponsored by Outlook Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06190093's enrollment target sits among peer trials
400 922nd of 2000 higher than 1,039 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI